1. Articles from emmarcourt

    1-3 of 3
    1. WeWork Board Members are Talking About Ousting CEO Adam Neumann Amid IPO Turmoil

      WeWork Board Members are Talking About Ousting CEO Adam Neumann Amid IPO Turmoil
      • Some board members at coworking startup WeWork aim to push out CEO Adam Neumann, according to a report from the Wall Street Journal.
      • The board could meet this week and might discuss Neumann becoming WeWork's nonexecutive chairman, the Journal reported.
      • According to the report, it was unclear how all of the company's seven directors — a list that includes Adam Neumann himself — have sided...
      Read Full Article
      Mentions: IPO WeWork
    2. Bristol-Myers Squibb has $2.2 Billion at Stake if its Deal to Acquire Celgene Falls Apart, and Opposition is Mounting

      Bristol-Myers Squibb has $2.2 Billion at Stake if its Deal to Acquire Celgene Falls Apart, and Opposition is Mounting
      • Opposition to pharmaceutical company Bristol-Myers Squibb's $74 billion acquisition of Celgene is growing.

      • The deal is facing pushback from Bristol-Myers' second-largest shareholder, the investment firm Wellington Management, as well as from activist investor Starboard Value.

      • If Bristol-Myers shareholders oppose the deal at an April meeting, the pharma giant may owe Celgene $2.2 billion and other fees...

      Read Full Article
    3. David Tepper’s Appaloosa Hedge Fund just Slammed the Leadership of $50 Billion Drugmaker Allergan, and is Calling for Change

      David Tepper’s Appaloosa Hedge Fund just Slammed the Leadership of $50 Billion Drugmaker Allergan, and is Calling for Change
      • Billionaire David Tepper's Appaloosa LP made a strongly-worded call for change to drugmaker Allergan's board leadership structure on Tuesday.
      • Appaloosa wants Allergan's board to separate the role of chairman and CEO, which today are both held by Allergan's Brent Saunders.
      • In a Tuesday letter, Appaloosa slammed Allergan's executive decision-making, "the record for which has been fraught with ill-considered initiatives and self-inflicted wounds for several years now."..
      Read Full Article
    1-3 of 3
  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, In the News, Partner Publications, Sponsored Content
  2. Topics in the News

    1. (2 articles) Board of Directors
    2. (2 articles) Wall Street
    3. (1 articles) Leadership
    4. (1 articles) Bloomberg
    5. (1 articles) Shire
    6. (1 articles) Starboard Value
    7. (1 articles) Allergan
    8. (1 articles) Leadership Structure
    9. (1 articles) Takeda
    10. (1 articles) Hedge Fund
    11. (1 articles) Geoffrey Shiu Fei Ling
    12. (1 articles) Sharon Tetlow
    13. (1 articles) Brian Chesky
    14. (1 articles) Amy Lynn Butewicz
    15. (1 articles) Airbnb
    16. (1 articles) UMH Properties, Inc.
    17. (1 articles) Catalyst Biosciences, Inc.
  3. Popular Articles

  4. Picture Gallery

    David Tepper’s Appaloosa Hedge Fund just Slammed the Leadership of $50 Billion Drugmaker Allergan, and is Calling for Change Bristol-Myers Squibb has $2.2 Billion at Stake if its Deal to Acquire Celgene Falls Apart, and Opposition is Mounting WeWork Board Members are Talking About Ousting CEO Adam Neumann Amid IPO Turmoil Catalyst Biosciences Announces Addition of Geoffrey Shiu Fei Ling, M.D. and Sharon Tetlow to Board of Directors UMH Properties, Inc. Expands Board of Directors and Appoints New Member Airbnb Imagines a ‘Stakeholder’ World Activist Shareholder Group Sells Entire Primo Water Stake Tilson Appoints Sheryl Tullis to Board of Directors Metalla Strengthens Board of Directors The Rite Aid Board Prescription: Complete The Director Refill Q2Earth Appoints Douglas Baum, Senior Biosciences Executive, To Board of Directors Zscaler Announces Election of David Schneider to its Board of Directors